Ophirex Stock

Ophirex is developing affordable, accessible, oral treatments to snakebite.

Sign up today and learn more about Ophirex Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About Ophirex Stock

Ophirex, is developing a first in class drug that will help the 500,000 people who die or suffer amputations each year from venomous snakebite. 70% of those who die never even make it to the hospital for treatment. Because Ophirex's drug will be available in an oral formulation, all that will change. Our drug is a small molecule inhibitor that targets the most lethal component of venom, so it will be effective against the most dangerous snakes.

Funding History

March 2022$16.5M
January 2023$37.0M

Management

CMO/CSO & Founder

Matthew Lewin

Press

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As:

Logo